Kymera Therapeutics, Inc. (KYMR) Stock Forecast
KYMR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.62 / 5 from 24 analysts
- Price target
- $139.35 average of analyst targets
- Upside to target
- +33.0% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-1.26
- 52-week range
- $55.80 – $127.31
KYMR analyst ratings
24 analystsNumber of analysts at each rating.
KYMR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KYMR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.27 | −$1.47 | −$1.04 | −$0.94 | −34.7% | 21 |
| Current fiscal year (2026) | −$3.85 | −$4.29 | −$3.13 | −$3.69 | −4.3% | 21 |
| Next fiscal year (2027) | −$5.10 | −$7.55 | −$3.27 | −$3.85 | −32.4% | 21 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KYMR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.9M | −$1.0M | $20.0M | +6.7% | 20 |
| Current fiscal year (2026) | $104.8M | $97.0M | $139.0M | +167.2% | 23 |
| Next fiscal year (2027) | $40.7M | −$13.0M | $97.9M | −61.2% | 22 |
KYMR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KYMR revenue: reported and forecast
KYMR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.03 | −$1.24 | −$1.25 | −$1.26 | −$1.27 | +23.3% | 2 up · 11 down |
| Current fiscal year (2026) | −$3.51 | −$3.80 | −$3.81 | −$3.84 | −$3.85 | +9.6% | 3 up · 11 down |
| Next fiscal year (2027) | −$4.35 | −$4.96 | −$4.97 | −$5.09 | −$5.10 | +17.2% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KYMR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KYMR beat in 7 of 12.
What analysts expect from KYMR
24 analysts cover Kymera Therapeutics; their consensus rating is strong buy (4.62 on a 1–5 scale, where 5 is a strong buy). The average price target is $139.35, 33.0% above the latest close of $104.78. Analysts expect earnings of −$3.85 per share for 2026, −4.3% from a year earlier. For 2027 the average estimate is −$5.10 per share on revenue of $40.7 million. Kymera Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: KYMR income statement, KYMR key metrics, KYMR chart. See the KYMR stock overview for the latest quote and news.
KYMR forecast FAQ
What is Kymera Therapeutics's price target?
The average analyst price target for Kymera Therapeutics is $139.35, 33.0% above the latest close of $104.78.
Is Kymera Therapeutics a buy, hold or sell?
Of 24 analysts covering Kymera Therapeutics, 17 rate it a strong buy, 5 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Kymera Therapeutics's EPS forecast?
Analysts forecast −$3.85 per share for 2026 (range −$4.29 to −$3.13); for 2027 the estimate is −$5.10.
What is Kymera Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $104.8 million, growth of 167.2%; for 2027 it is $40.7 million.
When does Kymera Therapeutics report earnings?
Kymera Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $-1.26.
Does Kymera Therapeutics usually beat earnings estimates?
Kymera Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.